| scholarly article | Q13442814 |
| P50 | author | Henry C Pitot | Q107054204 |
| Michelle R. Mahoney | Q112326955 | ||
| P2093 | author name string | Joel Picus | |
| Philip A Philip | |||
| Lisa Horvath | |||
| Noelle K Loconte | |||
| George P Kim | |||
| Kyle D Holen | |||
| Sam J Lubner | |||
| Wei-Peng Yong | |||
| Guy Van Hazel | |||
| Charles E Erlichman | |||
| Jill L Kolesar | |||
| P2860 | cites work | Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun | Q45309210 |
| Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. | Q46484712 | ||
| Gallbladder cancer, a different disease that needs individual trials | Q46761599 | ||
| Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer | Q46972019 | ||
| The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma. | Q53600008 | ||
| Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells | Q57424613 | ||
| One-sample multiple testing procedure for phase II clinical trials | Q70365924 | ||
| Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model | Q74086906 | ||
| Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma | Q80075002 | ||
| K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
| Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer | Q28308193 | ||
| Cancer statistics, 2009 | Q29547625 | ||
| Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer | Q29614302 | ||
| Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study | Q33362191 | ||
| Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial | Q33365628 | ||
| Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. | Q33382749 | ||
| Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study | Q33383423 | ||
| Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study | Q33385766 | ||
| Risk factors for biliary tract carcinogenesis | Q33705452 | ||
| Biliary tract cancers. | Q33760399 | ||
| Phase II study of erlotinib in patients with advanced biliary cancer | Q33997258 | ||
| The price tag on progress--chemotherapy for colorectal cancer | Q34335201 | ||
| Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials | Q34576456 | ||
| Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer | Q34618537 | ||
| A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer | Q36509678 | ||
| Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors | Q36623600 | ||
| A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer | Q37357251 | ||
| A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer | Q38496967 | ||
| Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice | Q40971116 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| multicenter clinical trial | Q6934595 | ||
| bevacizumab | Q413299 | ||
| erlotinib | Q418369 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 3491-3497 | |
| P577 | publication date | 2010-06-07 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study | |
| P478 | volume | 28 |
Search more.